“It has been suspected for a lot of years that BPA is involved in autism, but there was no direct evidence,” said T. Peter Stein, of RowanSOM and the study’s lead author. “We’ve shown there is a link. The metabolism of BPA is different in some children with autism than it is in otherwise healthy children.”
The research team – which included Margaret Schluter and Robert Steer, of RowanSOM who were responsible for laboratory analysis, and child neurologist Xue Ming, of NJMS who recruited and ascertained the study populations – examined urine specimens from 46 children with ASD and 52 healthy control children for both free BPA and total BPA concentrations. Like many chemicals, BPA becomes water soluble when it is bound to glucose in the liver – a process called glucuronidation. Conversion to a glucuronide and then excretion of the glucuronide in the urine is a major pathway for removing toxins from the body.
The researchers also conducted a metabolomic analysis to screen for all the chemicals found in the children’s urine. The metabolomics analyses showed the mean number of statistically significant correlations between metabolites detected and total BPA excreted to be approximately three times greater with the ASD group than the controls, and the number of statistical significant correlations with fraction of BPA bound was approximately15 times higher in the children with ASD (p<0.001).
“Other studies involving rodent data have shown that BPA functions as an endocrine disruptor, but ours is the first to show this in humans and the first to associate it to autism,” Stein said. “The observations show that for some children there was a relationship between intermediary metabolism, the ability to conjugate BPA and symptoms of autism.”
Although the study involves a relatively small number of subjects, Stein said, “The key point is that the study seems to link BPA to autism and creates an open area for further research. One implication of our study is that there might be a benefit to reducing BPA exposure for pregnant women and for children with autism.”
This research was supported by grants from the New Jersey Governor’s Council for Medical Research and Treatment of Autism and the National Institutes of Health, and by a contract with the U.S. Department of Defense.
Journalists interested in speaking with the researchers involved in this study should contact Jerry Carey, Rowan University Media and Public Relations, at [email protected] or by calling 856-566-6171.
About Rowan UniversityRowan University is a state-designated public research institution with campuses in Glassboro, Camden and Stratford, N.J., that offers bachelor’s through doctoral programs to 14,000 students. With its Camden-based Cooper Medical School of Rowan University and the Stratford-based School of Osteopathic Medicine, Rowan is only the second university in the nation to grant both M.D. and D.O. medical degrees.
RSS